Conference Track

Clinical Update on First-Line Antiretroviral Therapy

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Improved Outcomes in SMART Study Patients Resuming ART but With Residual Effects of Treatment Interruption
CASTLE: Atazanavir/Ritonavir Once Daily Noninferior to Lopinavir/Ritonavir Twice Daily in Therapy-Naive Patients
Maraviroc Failure in Treatment-Naive Patients in MERIT Trial: Role of Pretreatment Tropism Switches and Patient Nonadherence
Extended 14-Week Nevirapine or Nevirapine Plus Zidovudine Protective Against Death and HIV Infection in Breastfed Infants
High Response Rates to NNRTI-Based Therapy Despite Previous Single-Dose Nevirapine Exposure
Once-Daily Emtricitabine, Didanosine, and Efavirenz Safe, Effective in Pediatric Patients With HIV-1 Infection
Treatment Interruption Safe and Effective in Substantial Proportion of Patients With Acute and Recent HIV-1 Infection
HEAT Trial: Abacavir/Lamivudine Noninferior to Tenofovir/Emtricitabine in Treatment-Naive Patients Receiving Once-Daily Lopinavir/Ritonavir
Virologic Efficacy and Safety of Once-Daily Lopinavir/Ritonavir Tablet Noninferior to Twice-Daily Tablet in Treatment-Naive Patients
Low CD4+ Cell Count, Black Race, Female Sex, Younger Age Associated With Virologic Failure in ACTG 5142
Interrupted ART Noninferior to Continuous ART but Associated With NNRTI Resistance in West African Patients
2 Dual PI Regimens Associated With Insufficient Week 16 Virologic Success Rates in Treatment-Naive Patients
Multiple Study Design Factors Independently Influence Efficacy, Toxicity Outcomes of Antiretroviral Regimens

Expert Analysis

Clinical Update on First-Line Antiretroviral Therapy

Faculty:
Joel E. Gallant, MD, MPH Charles B. Hicks, MD Kathleen E. Squires, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new findings regarding the effects of delaying or interrupting antiretroviral therapy
Describe new data from randomized studies comparing different boosted PIs and different NRTI backbones in first-line antiretroviral therapy
Cite new insights regarding cardiovascular risks associated with antiretroviral therapy
Recount new findings regarding the use of antiretroviral therapy in prevention of mother-to-child HIV transmission

CME CREDIT INFORMATION

Release Date: 03/27/08

Expiration Date: 03/26/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.3 contact hours (0.13 CEUs)

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.